Enter multiple symbols separated by commas

Theravance Reports Positive Study for Potential Asthma Drugs

Biopharmaceutical company Theravance said Monday it saw positive results from two midstage studies dealing with its developing asthma and chronic obstructive pulmonary disease treatments.

The company is collaborating with GlaxoSmithKline on both programs. In each study, the drug candidate was administered once-daily and was effective in increasing bronchodilation, or widening of the air passages in the lungs.

Theravance said it will progress with the '444' product, which GlaxoSmithKline initially discovered, as the lead candidate and continue to develop its discovered '797' product as a backup.

Shares of Theravance jumped $4.55, or 15%, to $34.25 in after-hours trading. The stock gained 20 cents to close at $29.70 on the Nasdaq Stock Market.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Cognac Massougnes Vintage 1805

    The last remaining bottle of a vintage cognac made during the Battle of Trafalgar has gone on sale for £148,320.

  • Jac Jagaciak

    One of Victoria's Secret's newest "angels," Monika "Jac" Jagaciak, talks about what it's like to be a lingerie model and her craziest shoot.

  • Jessica Alba

    The actress' company got burned after consumers came out in droves, saying the company's sunscreen doesn't provide much sun protection at all.

U.S. Video